<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585195</url>
  </required_header>
  <id_info>
    <org_study_id>A8081001</org_study_id>
    <secondary_id>PROFILE 1001</secondary_id>
    <nct_id>NCT00585195</nct_id>
  </id_info>
  <brief_title>A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer</brief_title>
  <acronym>PROFILE 1001</acronym>
  <official_title>PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor&#xD;
      cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor&#xD;
      tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma&#xD;
      kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is&#xD;
      the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 19, 2006</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>MTD: Dose level at which at most 1 of 6 participants experienced DLT within and including 28 days of treatment (during Cycle 1 [1 cycle=28 days]) with next higher dose having at least 2/3 or 2/6 participants experiencing a DLT. DLT was defined as any of following: Hematologic toxicities- 1) prolonged grade 4 neutropenia for &gt;7 days. 2) Febrile neutropenia: grade 4 neutropenia with fever greater than (&gt;) 38.5 degree Celsius, both sustained over a 24 hour period (3) neutropenic infection: greater than or equal to (&gt;=) Grade 3 neutropenia with Grade &gt;=3 infection. (4) Grade &gt;=3 thrombocytopenia with bleeding/grade 4 lasting &gt;=7 days. Other non-hematologic toxicity included: Grade 3/4 toxicities (except for alopecia, Grade 3/4 hypophosphatemia, grade 3 hypertension with controlled blood pressure [less than (&lt;) 140/90 millimeter of mercury, and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting/diarrhea must persist at grade 3/4 despite maximal medical therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>RP2D was defined as a dose below or equal to MTD, at which crizotinib was unlikely to cause a significant inhibition of CYP3A4 activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
    <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1</measure>
    <time_frame>Pre-dose, 2, 4 and 6 hours post dose on Cycle 1 Day 1</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 2 Day 1</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15</measure>
    <time_frame>Pre-dose on Cycle 1 Day 15</time_frame>
    <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1</measure>
    <time_frame>Pre-dose on Cycle 2 Day 1</time_frame>
    <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
    <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1</measure>
    <time_frame>Pre-dose, 2, 4 and 6 hours post dose on Cycle 1 Day 1</time_frame>
    <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15</time_frame>
    <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 2 Day 1</time_frame>
    <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
    <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1</measure>
    <time_frame>Pre-dose, 2, 4 and 6 hours post dose on Cycle 1 Day 1</time_frame>
    <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15</time_frame>
    <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 2 Day 1</time_frame>
    <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration of Crizotinib to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)</measure>
    <time_frame>up to 172 Months</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. AEs included both serious and all non-serious adverse events. TEAEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>Dose-limiting toxicity (DLT) was defined as any of the following: Hematologic- prolonged grade 4 neutropenia for &gt;7 days. Febrile neutropenia, defined as grade 4 neutropenia with fever greater than (&gt;)38.5 degree Celsius, both sustained over a 24 hour period, neutropenic infection: greater than or equal to (&gt;=)Grade 3 neutropenia with Grade &gt;=3 infection. Grade &gt;=3 thrombocytopenia with bleeding or grade 4 lasting &gt;=7 days Lymphopenia was not considered a DLT unless accompanied by infection. Other non-hematologic toxicity: Grade 3 or 4 toxicities (except for alopecia, Grade 3/4 hypophosphatemia, grade 3 hypertension with controlled blood pressure [less than (&lt;) 140/90], and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting or diarrhea must persist at grade 3 or 4 despite maximal medical therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of MidaZolam When Taken Alone or Taken With Crizotinib</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Day -7 (midazolam alone arm), pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Cycle 2 Day 1 (midaZolam with crizotinib arm)</time_frame>
    <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of MidaZolam When Taken Alone or Taken With Crizotinib</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Day -7 (midazolam alone arm), pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Cycle 2 Day 1 (midaZolam with crizotinib arm)</time_frame>
    <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Crizotinib When Taken With Food</measure>
    <time_frame>pre-dose, 1, 2, 4, 6, 8, 9, and 24 hours post-dose on Day -7</time_frame>
    <description>AUC0-24 of Crizotinib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken With Food</measure>
    <time_frame>pre-dose, 1, 2, 4, 6, 8, 9, and 24 hours post-dose on Day -7</time_frame>
    <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin</measure>
    <time_frame>pre-dose, 2, 4, 6, 8 and 10 hours on Cycle 1 Day 15 (Crizotinib alone arm) and Cycle 2 Day 1 (Crizotinib with Rifampin arm)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin</measure>
    <time_frame>pre-dose, 2, 4, 6, 8 and 10 hours on Cycle 1 Day 15 (Crizotinib alone) and Cycle 2 Day 1 (Crizotinib with Rifampin)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin</measure>
    <time_frame>pre-dose on Cycle 1 Day 15 (Crizotinib alone arm) and Cycle 2 Day 1 (Crizotinib with Rifampin arm)</time_frame>
    <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole</measure>
    <time_frame>pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15 (Crizotinib with itraconazole) and Cycle 2 Day 1 (itraconazole alone)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole</measure>
    <time_frame>pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15 (Crizotinib with itraconazole) and Cycle 2 Day 1 (itraconazole alone)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole</measure>
    <time_frame>pre-dose on Cycle 1 Day 15 (crizotinib with itraconazole) and Cycle 2 Day 1 (itraconazole alone)</time_frame>
    <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)</measure>
    <time_frame>Baseline up to 172 months</time_frame>
    <description>ORR was defined as participants with a best overall response of complete response (CR) or partial response (PR) divided by the total number of evaluable participants per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)</measure>
    <time_frame>From first documentation of response to date of PD or death due to any cause (up to 172 months)</time_frame>
    <description>Duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of progressive disease (PD) or death due to any cause. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)</measure>
    <time_frame>From first dose until first documented response of PR or CR (up to 172 months)</time_frame>
    <description>TTR: time between first dose until first documented response of PR or CR. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Disease control was defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Disease control was defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)</measure>
    <time_frame>From randomization until PD or death, whichever occurred first (up to 172 months)</time_frame>
    <description>Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6</measure>
    <time_frame>From randomization to 6 months</time_frame>
    <description>Probability of being event free (event defined as PD or death due to any cause) at 6 months after the first dose of crizotinib was reported. PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)</measure>
    <time_frame>From randomization date to the date of death (up to 172 Months)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Probability of Participant Survival at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Probability of survival was defined as the probability of being alive at Month 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Probability of Participant Survival at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Probability of survival was defined as the probability of being alive at Month 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 1 Day 15</measure>
    <time_frame>Baseline, Cycle 1 Day 15</time_frame>
    <description>Geometric mean of ratio (Cycle1Day15/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 2 Day 1</measure>
    <time_frame>Baseline, Cycle 2 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 2 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 4 Day 1</measure>
    <time_frame>Baseline, Cycle 4 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 4 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 6 Day 1</measure>
    <time_frame>Baseline, Cycle 6 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 6 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 9 Day 1</measure>
    <time_frame>Baseline, Cycle 9 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 9 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 12 Day 1</measure>
    <time_frame>Baseline, Cycle 12 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 12 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 15 Day 1</measure>
    <time_frame>Baseline, Cycle 15 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 15 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 18 Day 1</measure>
    <time_frame>Baseline, Cycle 18 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 18 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 21 Day 1</measure>
    <time_frame>Baseline, Cycle 21 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 21 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 24 Day 1</measure>
    <time_frame>Baseline, Cycle 24 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 24 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 27 Day 1</measure>
    <time_frame>Baseline, Cycle 27 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 27 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 30 Day 1</measure>
    <time_frame>Baseline, Cycle 30 Day 1</time_frame>
    <description>Geometric mean of ratio (Cycle 30 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at End of Treatment</measure>
    <time_frame>Baseline, End of Treatment (28 days post last dose)</time_frame>
    <description>Geometric mean of ratio (End of treatment/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">590</enrollment>
  <condition>Non-Small Cell Lung Cancer ALK-positive</condition>
  <condition>Non-Small Cell Lung Cancer c-Met Dependent</condition>
  <condition>Non-Small Cell Lung Cancer ROS Marker Positive</condition>
  <condition>Systemic Anaplastic Large-Cell Lymphoma</condition>
  <condition>Advanced Malignancies Except Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02341066</intervention_name>
    <description>Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced malignancies (except leukemias), histologically proven at diagnosis;&#xD;
             Histologically confirmed advanced malignancies that are known to be sensitive to&#xD;
             PF-03241066 inhibition, e.g. ALK, c-MET and ROS&#xD;
&#xD;
          -  Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients&#xD;
             with non-measurable disease may enter on a case-by-case basis); not required for DDI&#xD;
             sub-studies.&#xD;
&#xD;
          -  Adequate blood cell counts, kidney function, liver function and Eastern Cooperative&#xD;
             Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG&#xD;
             score of 2 may be allowed on a case-by-case basis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of&#xD;
             starting study treatment, depending on the patient cohort&#xD;
&#xD;
          -  Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma&#xD;
&#xD;
          -  Active or unstable cardiac disease or heart attack within 3 months of starting study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital/ Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston Inc.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Beetham Eye Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kresge Eye Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center: Breast and Imaging Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Eye and Ear Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Martha Morehouse Medical Plaza</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Vermont Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi cancer center central hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8081001&amp;StudyName=A%20Study%20Of%20Oral%20PF-02341066%2C%20A%20c-Met/Hepatocyte%20Growth%20Factor%20Tyrosine%20Kinase%20Inhibitor%2C%20In%20Patients%20With%20Advanced%20Cancer</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 29, 2007</study_first_submitted>
  <study_first_submitted_qc>December 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <results_first_submitted>July 30, 2021</results_first_submitted>
  <results_first_submitted_qc>September 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2021</results_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crizotinib</keyword>
  <keyword>dose-finding</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>ALK rearrangements</keyword>
  <keyword>c-Met mutations or amplifications</keyword>
  <keyword>c-Met dependent tumors</keyword>
  <keyword>ROS1 rearrangements</keyword>
  <keyword>c-Met exon 14 deletion</keyword>
  <keyword>c-Met exon 14 skipping</keyword>
  <keyword>c-Met exon 14 alterations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT00585195/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT00585195/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was a lead-in period of 7 days in which single-dose pharmacokinetics of Crizotinib or midazolam was characterized on Day-7, prior to initiation of continuous dosing in the first cycle (each cycle 28 days) of treatment in dose escalation cohorts and recommended phase 2 dose (RP2D) cohorts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
          <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
          <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
        </group>
        <group group_id="P3">
          <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
          <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P4">
          <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
          <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P5">
          <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P6">
          <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
          <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
        </group>
        <group group_id="P7">
          <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
          <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P8">
          <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
          <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P9">
          <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
          <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P10">
          <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
          <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P11">
          <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
          <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P12">
          <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P13">
          <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P14">
          <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P15">
          <title>RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days).</description>
        </group>
        <group group_id="P16">
          <title>RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).</description>
        </group>
        <group group_id="P17">
          <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P18">
          <title>RP2D Cohort: Enriched Other: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="P19">
          <title>RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole</title>
          <description>Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.</description>
        </group>
        <group group_id="P20">
          <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.</description>
        </group>
        <group group_id="P21">
          <title>RP2D Cohort: Midazolam Interaction: Crizotinib 250 mg +Midazolam</title>
          <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID with or without food from Day 1 Cycle 1 up to 133 cycles (each cycle 28 days). Participants also received single 2 mg oral dose of Midazolam on Day -7 and another single 2-mg oral dose of Midazolam concurrently with Crizotinib on Cycle 2 Day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="11"/>
                <participants group_id="P12" count="53"/>
                <participants group_id="P13" count="85"/>
                <participants group_id="P14" count="41"/>
                <participants group_id="P15" count="48"/>
                <participants group_id="P16" count="19"/>
                <participants group_id="P17" count="154"/>
                <participants group_id="P18" count="67"/>
                <participants group_id="P19" count="21"/>
                <participants group_id="P20" count="18"/>
                <participants group_id="P21" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="53"/>
                <participants group_id="P13" count="85"/>
                <participants group_id="P14" count="41"/>
                <participants group_id="P15" count="48"/>
                <participants group_id="P16" count="18"/>
                <participants group_id="P17" count="154"/>
                <participants group_id="P18" count="66"/>
                <participants group_id="P19" count="18"/>
                <participants group_id="P20" count="18"/>
                <participants group_id="P21" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="11"/>
                <participants group_id="P12" count="53"/>
                <participants group_id="P13" count="85"/>
                <participants group_id="P14" count="41"/>
                <participants group_id="P15" count="48"/>
                <participants group_id="P16" count="19"/>
                <participants group_id="P17" count="154"/>
                <participants group_id="P18" count="67"/>
                <participants group_id="P19" count="21"/>
                <participants group_id="P20" count="18"/>
                <participants group_id="P21" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="4"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="14"/>
                <participants group_id="P18" count="9"/>
                <participants group_id="P19" count="2"/>
                <participants group_id="P20" count="3"/>
                <participants group_id="P21" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="25"/>
                <participants group_id="P13" count="29"/>
                <participants group_id="P14" count="26"/>
                <participants group_id="P15" count="21"/>
                <participants group_id="P16" count="12"/>
                <participants group_id="P17" count="94"/>
                <participants group_id="P18" count="42"/>
                <participants group_id="P19" count="4"/>
                <participants group_id="P20" count="9"/>
                <participants group_id="P21" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="15"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="2"/>
                <participants group_id="P20" count="2"/>
                <participants group_id="P21" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="19"/>
                <participants group_id="P13" count="23"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="11"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="28"/>
                <participants group_id="P18" count="12"/>
                <participants group_id="P19" count="10"/>
                <participants group_id="P20" count="4"/>
                <participants group_id="P21" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="3"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="11"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn Due to Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis (SA) set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
          <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
          <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
        </group>
        <group group_id="B3">
          <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
          <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B4">
          <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
          <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B5">
          <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B6">
          <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
          <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
        </group>
        <group group_id="B7">
          <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
          <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B8">
          <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
          <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B9">
          <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
          <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B10">
          <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
          <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B11">
          <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
          <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B12">
          <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B13">
          <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B14">
          <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B15">
          <title>RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days).</description>
        </group>
        <group group_id="B16">
          <title>RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).</description>
        </group>
        <group group_id="B17">
          <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B18">
          <title>RP2D Cohort: Enriched Other: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="B19">
          <title>RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole</title>
          <description>Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.</description>
        </group>
        <group group_id="B20">
          <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.</description>
        </group>
        <group group_id="B21">
          <title>RP2D Cohort: Midazolam Interaction: Crizotinib 250 mg +Midazolam</title>
          <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID with or without food from Day 1 Cycle 1 up to 133 cycles (each cycle 28 days). Participants also received single 2 mg oral dose of Midazolam on Day -7 and another single 2-mg oral dose of Midazolam concurrently with Crizotinib on Cycle 2 Day 1</description>
        </group>
        <group group_id="B22">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="9"/>
            <count group_id="B12" value="53"/>
            <count group_id="B13" value="85"/>
            <count group_id="B14" value="41"/>
            <count group_id="B15" value="48"/>
            <count group_id="B16" value="18"/>
            <count group_id="B17" value="154"/>
            <count group_id="B18" value="66"/>
            <count group_id="B19" value="18"/>
            <count group_id="B20" value="18"/>
            <count group_id="B21" value="12"/>
            <count group_id="B22" value="578"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>less than 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="23"/>
                    <measurement group_id="B13" value="18"/>
                    <measurement group_id="B14" value="20"/>
                    <measurement group_id="B15" value="30"/>
                    <measurement group_id="B16" value="12"/>
                    <measurement group_id="B17" value="131"/>
                    <measurement group_id="B18" value="51"/>
                    <measurement group_id="B19" value="9"/>
                    <measurement group_id="B20" value="12"/>
                    <measurement group_id="B21" value="9"/>
                    <measurement group_id="B22" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than or equals to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="30"/>
                    <measurement group_id="B13" value="67"/>
                    <measurement group_id="B14" value="21"/>
                    <measurement group_id="B15" value="18"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="23"/>
                    <measurement group_id="B18" value="15"/>
                    <measurement group_id="B19" value="9"/>
                    <measurement group_id="B20" value="6"/>
                    <measurement group_id="B21" value="3"/>
                    <measurement group_id="B22" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="30"/>
                    <measurement group_id="B13" value="48"/>
                    <measurement group_id="B14" value="19"/>
                    <measurement group_id="B15" value="24"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="80"/>
                    <measurement group_id="B18" value="25"/>
                    <measurement group_id="B19" value="11"/>
                    <measurement group_id="B20" value="9"/>
                    <measurement group_id="B21" value="8"/>
                    <measurement group_id="B22" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="23"/>
                    <measurement group_id="B13" value="37"/>
                    <measurement group_id="B14" value="22"/>
                    <measurement group_id="B15" value="24"/>
                    <measurement group_id="B16" value="10"/>
                    <measurement group_id="B17" value="74"/>
                    <measurement group_id="B18" value="41"/>
                    <measurement group_id="B19" value="7"/>
                    <measurement group_id="B20" value="9"/>
                    <measurement group_id="B21" value="4"/>
                    <measurement group_id="B22" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="30"/>
                    <measurement group_id="B13" value="60"/>
                    <measurement group_id="B14" value="38"/>
                    <measurement group_id="B15" value="35"/>
                    <measurement group_id="B16" value="11"/>
                    <measurement group_id="B17" value="98"/>
                    <measurement group_id="B18" value="49"/>
                    <measurement group_id="B19" value="13"/>
                    <measurement group_id="B20" value="16"/>
                    <measurement group_id="B21" value="11"/>
                    <measurement group_id="B22" value="418"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="4"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B20" value="2"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="21"/>
                    <measurement group_id="B13" value="15"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="9"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="43"/>
                    <measurement group_id="B18" value="9"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="4"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="1"/>
                    <measurement group_id="B22" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib</title>
        <description>MTD: Dose level at which at most 1 of 6 participants experienced DLT within and including 28 days of treatment (during Cycle 1 [1 cycle=28 days]) with next higher dose having at least 2/3 or 2/6 participants experiencing a DLT. DLT was defined as any of following: Hematologic toxicities- 1) prolonged grade 4 neutropenia for &gt;7 days. 2) Febrile neutropenia: grade 4 neutropenia with fever greater than (&gt;) 38.5 degree Celsius, both sustained over a 24 hour period (3) neutropenic infection: greater than or equal to (&gt;=) Grade 3 neutropenia with Grade &gt;=3 infection. (4) Grade &gt;=3 thrombocytopenia with bleeding/grade 4 lasting &gt;=7 days. Other non-hematologic toxicity included: Grade 3/4 toxicities (except for alopecia, Grade 3/4 hypophosphatemia, grade 3 hypertension with controlled blood pressure [less than (&lt;) 140/90 millimeter of mercury, and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting/diarrhea must persist at grade 3/4 despite maximal medical therapy.</description>
        <time_frame>Cycle 1 (28 days)</time_frame>
        <population>Safety analysis (SA) set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib</title>
          <description>MTD: Dose level at which at most 1 of 6 participants experienced DLT within and including 28 days of treatment (during Cycle 1 [1 cycle=28 days]) with next higher dose having at least 2/3 or 2/6 participants experiencing a DLT. DLT was defined as any of following: Hematologic toxicities- 1) prolonged grade 4 neutropenia for &gt;7 days. 2) Febrile neutropenia: grade 4 neutropenia with fever greater than (&gt;) 38.5 degree Celsius, both sustained over a 24 hour period (3) neutropenic infection: greater than or equal to (&gt;=) Grade 3 neutropenia with Grade &gt;=3 infection. (4) Grade &gt;=3 thrombocytopenia with bleeding/grade 4 lasting &gt;=7 days. Other non-hematologic toxicity included: Grade 3/4 toxicities (except for alopecia, Grade 3/4 hypophosphatemia, grade 3 hypertension with controlled blood pressure [less than (&lt;) 140/90 millimeter of mercury, and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting/diarrhea must persist at grade 3/4 despite maximal medical therapy.</description>
          <population>Safety analysis (SA) set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
          <units>milligram</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="250"/>
                    <measurement group_id="O4" value="250"/>
                    <measurement group_id="O5" value="250"/>
                    <measurement group_id="O6" value="250"/>
                    <measurement group_id="O7" value="250"/>
                    <measurement group_id="O8" value="250"/>
                    <measurement group_id="O9" value="250"/>
                    <measurement group_id="O10" value="250"/>
                    <measurement group_id="O11" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib</title>
        <description>RP2D was defined as a dose below or equal to MTD, at which crizotinib was unlikely to cause a significant inhibition of CYP3A4 activity.</description>
        <time_frame>Cycle 1 (28 days)</time_frame>
        <population>Safety analysis (SA) set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib</title>
          <description>RP2D was defined as a dose below or equal to MTD, at which crizotinib was unlikely to cause a significant inhibition of CYP3A4 activity.</description>
          <population>Safety analysis (SA) set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
          <units>milligram</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="250"/>
                    <measurement group_id="O4" value="250"/>
                    <measurement group_id="O5" value="250"/>
                    <measurement group_id="O6" value="250"/>
                    <measurement group_id="O7" value="250"/>
                    <measurement group_id="O8" value="250"/>
                    <measurement group_id="O9" value="250"/>
                    <measurement group_id="O10" value="250"/>
                    <measurement group_id="O11" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7</title>
        <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (0-inf).</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. &quot;Overall number of participants analyzed (N)&quot; signifies participants evaluable for this outcome measure (OM). Data for this OM was planned to be collected for individual arms of low and high dose escalation and combined RP2D Cohort excluding &quot;Low Dose Escalation Cohort: Crizotinib 100 mg QD&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7</title>
          <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (0-inf).</description>
          <population>Pharmacokinetic (PK) parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. &quot;Overall number of participants analyzed (N)&quot; signifies participants evaluable for this outcome measure (OM). Data for this OM was planned to be collected for individual arms of low and high dose escalation and combined RP2D Cohort excluding &quot;Low Dose Escalation Cohort: Crizotinib 100 mg QD&quot; arm.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.43" spread="22"/>
                    <measurement group_id="O2" value="1378.05" spread="144"/>
                    <measurement group_id="O3" value="946.93" spread="38"/>
                    <measurement group_id="O4" value="1817.35" spread="34"/>
                    <measurement group_id="O5" value="2320.00"/>
                    <measurement group_id="O6" value="3457" spread="42"/>
                    <measurement group_id="O7" value="3078" spread="119"/>
                    <measurement group_id="O8" value="2107" spread="53"/>
                    <measurement group_id="O9" value="3979" spread="39"/>
                    <measurement group_id="O10" value="7547" spread="76"/>
                    <measurement group_id="O11" value="2489.39" spread="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7</title>
        <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
        <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be reported for individual arms of low and high dose escalation and combined RP2D Cohort excluding &quot;Low Dose Escalation Cohort: Crizotinib 100 mg QD&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7</title>
          <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
          <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be reported for individual arms of low and high dose escalation and combined RP2D Cohort excluding &quot;Low Dose Escalation Cohort: Crizotinib 100 mg QD&quot; arm.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.40" spread="8"/>
                    <measurement group_id="O2" value="658.64" spread="136"/>
                    <measurement group_id="O3" value="338.39" spread="50"/>
                    <measurement group_id="O4" value="558.01" spread="33"/>
                    <measurement group_id="O5" value="863.00"/>
                    <measurement group_id="O6" value="1731" spread="51"/>
                    <measurement group_id="O7" value="1377" spread="114"/>
                    <measurement group_id="O8" value="1300" spread="61"/>
                    <measurement group_id="O9" value="1906" spread="39"/>
                    <measurement group_id="O10" value="3423" spread="57"/>
                    <measurement group_id="O11" value="741.50" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1</title>
        <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
        <time_frame>Pre-dose, 2, 4 and 6 hours post dose on Cycle 1 Day 1</time_frame>
        <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for low dose escalation cohort (excluding Crizotinib 50 mg QD, Crizotinib 200 mg QD and Crizotinib 250 mg BID arms) and combined RP2D cohort and was not planned to be collected for high dose escalation cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1</title>
          <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
          <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for low dose escalation cohort (excluding Crizotinib 50 mg QD, Crizotinib 200 mg QD and Crizotinib 250 mg BID arms) and combined RP2D cohort and was not planned to be collected for high dose escalation cohort.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="457.55" spread="32"/>
                    <measurement group_id="O2" value="383.98" spread="10"/>
                    <measurement group_id="O3" value="763.71" spread="57"/>
                    <measurement group_id="O4" value="663.39" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15</title>
        <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15</time_frame>
        <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts and combined RP2D Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O12">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15</title>
          <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
          <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts and combined RP2D Cohort.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.13" spread="76"/>
                    <measurement group_id="O2" value="1086.99" spread="34"/>
                    <measurement group_id="O3" value="2047.13" spread="45"/>
                    <measurement group_id="O4" value="1780.21" spread="69"/>
                    <measurement group_id="O5" value="3083.93" spread="31"/>
                    <measurement group_id="O6" value="4066.67" spread="53"/>
                    <measurement group_id="O7" value="4375" spread="34"/>
                    <measurement group_id="O8" value="3385" spread="24"/>
                    <measurement group_id="O9" value="6655" spread="4"/>
                    <measurement group_id="O10" value="6362" spread="37"/>
                    <measurement group_id="O11" value="10480" spread="76"/>
                    <measurement group_id="O12" value="3879.56" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1</title>
        <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 2 Day 1</time_frame>
        <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts and combined RP2D Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O12">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1</title>
          <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 12 hours for BID dose and 24 hours for QD dose.</description>
          <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts and combined RP2D Cohort.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425.90" spread="49"/>
                    <measurement group_id="O2" value="1595.58" spread="30"/>
                    <measurement group_id="O3" value="1719.30" spread="68"/>
                    <measurement group_id="O4" value="2255.70" spread="14"/>
                    <measurement group_id="O5" value="3054.45" spread="29"/>
                    <measurement group_id="O6" value="3644.72" spread="17"/>
                    <measurement group_id="O7" value="4815" spread="23"/>
                    <measurement group_id="O8" value="3839" spread="65"/>
                    <measurement group_id="O9" value="6330" spread="64"/>
                    <measurement group_id="O10" value="7273" spread="48"/>
                    <measurement group_id="O11" value="8733" spread="63"/>
                    <measurement group_id="O12" value="4163.77" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15</title>
        <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
        <time_frame>Pre-dose on Cycle 1 Day 15</time_frame>
        <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for individual arms of low dose escalation and combined RP2D Cohort and not planned to be collected for high dose escalation cohort&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15</title>
          <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
          <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for individual arms of low dose escalation and combined RP2D Cohort and not planned to be collected for high dose escalation cohort&quot;.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.29" spread="42"/>
                    <measurement group_id="O2" value="32.61" spread="36"/>
                    <measurement group_id="O3" value="48.18" spread="58"/>
                    <measurement group_id="O4" value="126.76" spread="97"/>
                    <measurement group_id="O5" value="232.59" spread="33"/>
                    <measurement group_id="O6" value="307.83" spread="59"/>
                    <measurement group_id="O7" value="280.43" spread="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1</title>
        <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
        <time_frame>Pre-dose on Cycle 2 Day 1</time_frame>
        <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for individual arms of low dose escalation and combined RP2D Cohort and not planned to be collected for high dose escalation cohort&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1</title>
          <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
          <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for individual arms of low dose escalation and combined RP2D Cohort and not planned to be collected for high dose escalation cohort&quot;.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.68" spread="94"/>
                    <measurement group_id="O2" value="31.91" spread="34"/>
                    <measurement group_id="O3" value="54.04" spread="85"/>
                    <measurement group_id="O4" value="157.24" spread="17"/>
                    <measurement group_id="O5" value="232.45" spread="32"/>
                    <measurement group_id="O6" value="329.50" spread="40"/>
                    <measurement group_id="O7" value="312.99" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7</title>
        <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
        <population>PK parameter analysis population set. &quot;N&quot;=participants evaluable for this outcome measure. Data for this OM was planned to be collected for dose escalation cohorts (both low and high) and combined RP2D Cohort excluding &quot;Low Dose Escalation Cohort: Crizotinib 100 mg QD&quot; cohort arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7</title>
          <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
          <population>PK parameter analysis population set. &quot;N&quot;=participants evaluable for this outcome measure. Data for this OM was planned to be collected for dose escalation cohorts (both low and high) and combined RP2D Cohort excluding &quot;Low Dose Escalation Cohort: Crizotinib 100 mg QD&quot; cohort arms.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.19" spread="36"/>
                    <measurement group_id="O2" value="67.64" spread="106"/>
                    <measurement group_id="O3" value="55.73" spread="45"/>
                    <measurement group_id="O4" value="87.02" spread="34"/>
                    <measurement group_id="O5" value="130.00"/>
                    <measurement group_id="O6" value="184.7" spread="65"/>
                    <measurement group_id="O7" value="115.9" spread="85"/>
                    <measurement group_id="O8" value="146.6" spread="31"/>
                    <measurement group_id="O9" value="154.3" spread="30"/>
                    <measurement group_id="O10" value="270.9" spread="47"/>
                    <measurement group_id="O11" value="108.40" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1</title>
        <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
        <time_frame>Pre-dose, 2, 4 and 6 hours post dose on Cycle 1 Day 1</time_frame>
        <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for low dose escalation cohort (excluding Crizotinib 50 mg QD, Crizotinib 200 mg QD and Crizotinib 250 mg BID arms) and combined RP2D cohort and was not planned to be collected for high dose escalation cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1</title>
          <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
          <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for low dose escalation cohort (excluding Crizotinib 50 mg QD, Crizotinib 200 mg QD and Crizotinib 250 mg BID arms) and combined RP2D cohort and was not planned to be collected for high dose escalation cohort.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.89" spread="53"/>
                    <measurement group_id="O2" value="64.14" spread="2"/>
                    <measurement group_id="O3" value="114.09" spread="48"/>
                    <measurement group_id="O4" value="98.86" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15</title>
        <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15</time_frame>
        <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts (both low and high) and combined RP2D Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O12">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15</title>
          <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
          <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts (both low and high) and combined RP2D Cohort.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.44" spread="68"/>
                    <measurement group_id="O2" value="85.66" spread="66"/>
                    <measurement group_id="O3" value="149.06" spread="29"/>
                    <measurement group_id="O4" value="188.84" spread="56"/>
                    <measurement group_id="O5" value="326.51" spread="24"/>
                    <measurement group_id="O6" value="420.15" spread="46"/>
                    <measurement group_id="O7" value="315.2" spread="50"/>
                    <measurement group_id="O8" value="215.5" spread="26"/>
                    <measurement group_id="O9" value="395.3" spread="16"/>
                    <measurement group_id="O10" value="379.2" spread="28"/>
                    <measurement group_id="O11" value="671.3" spread="76"/>
                    <measurement group_id="O12" value="411.11" spread="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1</title>
        <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 2 Day 1</time_frame>
        <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts (both low and high) and combined RP2D Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O12">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1</title>
          <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
          <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts (both low and high) and combined RP2D Cohort.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.99" spread="23"/>
                    <measurement group_id="O2" value="133.69" spread="48"/>
                    <measurement group_id="O3" value="146.26" spread="38"/>
                    <measurement group_id="O4" value="238.84" spread="12"/>
                    <measurement group_id="O5" value="327.94" spread="25"/>
                    <measurement group_id="O6" value="474.68" spread="43"/>
                    <measurement group_id="O7" value="275.0" spread="28"/>
                    <measurement group_id="O8" value="248.2" spread="60"/>
                    <measurement group_id="O9" value="327.9" spread="47"/>
                    <measurement group_id="O10" value="419.8" spread="36"/>
                    <measurement group_id="O11" value="700.0" spread="37"/>
                    <measurement group_id="O12" value="477.85" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7</title>
        <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
        <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for individual arms of low and high dose escalation cohorts (excluding 'Low Dose Escalation Cohort: Crizotinib 100 mg QD' arm) and combined RP2D.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7</title>
          <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
          <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for individual arms of low and high dose escalation cohorts (excluding 'Low Dose Escalation Cohort: Crizotinib 100 mg QD' arm) and combined RP2D.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.75" upper_limit="4.08"/>
                    <measurement group_id="O2" value="4.09" lower_limit="1.08" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="4.00" upper_limit="4.08"/>
                    <measurement group_id="O4" value="4.00" lower_limit="1.00" upper_limit="8.95"/>
                    <measurement group_id="O5" value="2.02" lower_limit="2.02" upper_limit="2.02"/>
                    <measurement group_id="O6" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O7" value="2.15" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="4.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O9" value="4.00" lower_limit="1.98" upper_limit="6.00"/>
                    <measurement group_id="O10" value="4.99" lower_limit="2.15" upper_limit="6.13"/>
                    <measurement group_id="O11" value="4.00" lower_limit="2.00" upper_limit="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1</title>
        <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
        <time_frame>Pre-dose, 2, 4 and 6 hours post dose on Cycle 1 Day 1</time_frame>
        <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for low dose escalation cohorts (excluding Crizotinib 50 mg QD, Crizotinib 200 mg QD and Crizotinib 250 mg BID arms) and combined RP2D cohort and was not planned to be collected for high dose escalation cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1</title>
          <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
          <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for low dose escalation cohorts (excluding Crizotinib 50 mg QD, Crizotinib 200 mg QD and Crizotinib 250 mg BID arms) and combined RP2D cohort and was not planned to be collected for high dose escalation cohort.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" lower_limit="1.00" upper_limit="4.02"/>
                    <measurement group_id="O2" value="4.00" lower_limit="4.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.05" upper_limit="8.02"/>
                    <measurement group_id="O4" value="4.05" lower_limit="1.00" upper_limit="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15</title>
        <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15</time_frame>
        <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts (both low and high) and combined RP2D Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O12">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15</title>
          <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
          <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts (both low and high) and combined RP2D Cohort.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.51" lower_limit="0.00" upper_limit="6.08"/>
                    <measurement group_id="O3" value="4.07" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="5.01" lower_limit="2.08" upper_limit="8.03"/>
                    <measurement group_id="O5" value="4.00" lower_limit="0.97" upper_limit="6.07"/>
                    <measurement group_id="O6" value="4.99" lower_limit="3.98" upper_limit="6.22"/>
                    <measurement group_id="O7" value="5.13" lower_limit="1.93" upper_limit="7.88"/>
                    <measurement group_id="O8" value="5.17" lower_limit="0.933" upper_limit="6.00"/>
                    <measurement group_id="O9" value="4.00" lower_limit="4.00" upper_limit="9.00"/>
                    <measurement group_id="O10" value="5.98" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O11" value="5.03" lower_limit="4.00" upper_limit="6.03"/>
                    <measurement group_id="O12" value="4.00" lower_limit="0.00" upper_limit="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1</title>
        <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 2 Day 1</time_frame>
        <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts (both low and high) and combined RP2D Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O12">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1</title>
          <description>Tmax was defined as the time to reach the observed maximum plasma concentration (Cmax).</description>
          <population>The PK parameter analysis population included all participants treated (including Day -7 dose) who have at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data for this outcome measures was planned to be collected for individual arms of dose escalation cohorts (both low and high) and combined RP2D Cohort.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.98" lower_limit="2.00" upper_limit="4.02"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.00" upper_limit="4.17"/>
                    <measurement group_id="O4" value="4.00" lower_limit="3.95" upper_limit="4.00"/>
                    <measurement group_id="O5" value="4.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="4.05" lower_limit="3.98" upper_limit="9.00"/>
                    <measurement group_id="O7" value="3.00" lower_limit="1.00" upper_limit="5.95"/>
                    <measurement group_id="O8" value="4.00" lower_limit="2.08" upper_limit="6.00"/>
                    <measurement group_id="O9" value="7.59" lower_limit="6.18" upper_limit="9.00"/>
                    <measurement group_id="O10" value="4.30" lower_limit="4.00" upper_limit="9.00"/>
                    <measurement group_id="O11" value="5.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O12" value="4.00" lower_limit="0.00" upper_limit="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration of Crizotinib to decrease by one half.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 8, 9, 24, 48 and any two time points (72, 96, 120 and 144 hours) post-dose on Day -7</time_frame>
        <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for individual arms of low and high dose escalation cohort and combined RP2D cohort excluding &quot;Low Dose Escalation Cohort: Crizotinib 100 mg QD&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O6">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration of Crizotinib to decrease by one half.</description>
          <population>PK parameter analysis population included all participants treated (including Day -7 dose) who had at least 1 of the PK parameters of interest for Crizotinib. Here, &quot;N&quot; signifies participants evaluable for this OM. Data for this OM was planned to be collected for individual arms of low and high dose escalation cohort and combined RP2D cohort excluding &quot;Low Dose Escalation Cohort: Crizotinib 100 mg QD&quot; arm.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.20" lower_limit="45.50" upper_limit="56.80"/>
                    <measurement group_id="O2" value="46.70" lower_limit="30.40" upper_limit="67.20"/>
                    <measurement group_id="O3" value="52.60" lower_limit="51.70" upper_limit="53.50"/>
                    <measurement group_id="O4" value="47.35" lower_limit="36.80" upper_limit="57.70"/>
                    <measurement group_id="O5" value="45.70" lower_limit="45.70" upper_limit="45.70"/>
                    <measurement group_id="O6" value="43.33" lower_limit="35.4" upper_limit="52.3"/>
                    <measurement group_id="O7" value="49.06" lower_limit="33.2" upper_limit="79.3"/>
                    <measurement group_id="O8" value="46.36" lower_limit="43.0" upper_limit="49.8"/>
                    <measurement group_id="O9" value="42.17" lower_limit="28.3" upper_limit="53.8"/>
                    <measurement group_id="O10" value="38.78" lower_limit="30.9" upper_limit="55.3"/>
                    <measurement group_id="O11" value="43.20" lower_limit="27.10" upper_limit="63.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. AEs included both serious and all non-serious adverse events. TEAEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration.</description>
        <time_frame>up to 172 Months</time_frame>
        <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O12">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)</description>
          </group>
          <group group_id="O13">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O14">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O15">
            <title>RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days).</description>
          </group>
          <group group_id="O16">
            <title>RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).</description>
          </group>
          <group group_id="O17">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O18">
            <title>RP2D Cohort: Enriched Other: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O19">
            <title>RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole</title>
            <description>Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.</description>
          </group>
          <group group_id="O20">
            <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.</description>
          </group>
          <group group_id="O21">
            <title>RP2D Cohort: Midazolam Interaction: Crizotinib 250 mg +Midazolam</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID with or without food from Day 1 Cycle 1 up to 133 cycles (each cycle 28 days). Participants also received single 2 mg oral dose of Midazolam on Day -7 and another single 2-mg oral dose of Midazolam concurrently with Crizotinib on Cycle 2 Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. AEs included both serious and all non-serious adverse events. TEAEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration.</description>
          <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="53"/>
                <count group_id="O13" value="85"/>
                <count group_id="O14" value="41"/>
                <count group_id="O15" value="48"/>
                <count group_id="O16" value="18"/>
                <count group_id="O17" value="154"/>
                <count group_id="O18" value="66"/>
                <count group_id="O19" value="18"/>
                <count group_id="O20" value="18"/>
                <count group_id="O21" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="9"/>
                    <measurement group_id="O12" value="53"/>
                    <measurement group_id="O13" value="85"/>
                    <measurement group_id="O14" value="41"/>
                    <measurement group_id="O15" value="47"/>
                    <measurement group_id="O16" value="18"/>
                    <measurement group_id="O17" value="154"/>
                    <measurement group_id="O18" value="66"/>
                    <measurement group_id="O19" value="14"/>
                    <measurement group_id="O20" value="5"/>
                    <measurement group_id="O21" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="24"/>
                    <measurement group_id="O13" value="54"/>
                    <measurement group_id="O14" value="25"/>
                    <measurement group_id="O15" value="22"/>
                    <measurement group_id="O16" value="9"/>
                    <measurement group_id="O17" value="75"/>
                    <measurement group_id="O18" value="29"/>
                    <measurement group_id="O19" value="7"/>
                    <measurement group_id="O20" value="6"/>
                    <measurement group_id="O21" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)</title>
        <description>Dose-limiting toxicity (DLT) was defined as any of the following: Hematologic- prolonged grade 4 neutropenia for &gt;7 days. Febrile neutropenia, defined as grade 4 neutropenia with fever greater than (&gt;)38.5 degree Celsius, both sustained over a 24 hour period, neutropenic infection: greater than or equal to (&gt;=)Grade 3 neutropenia with Grade &gt;=3 infection. Grade &gt;=3 thrombocytopenia with bleeding or grade 4 lasting &gt;=7 days Lymphopenia was not considered a DLT unless accompanied by infection. Other non-hematologic toxicity: Grade 3 or 4 toxicities (except for alopecia, Grade 3/4 hypophosphatemia, grade 3 hypertension with controlled blood pressure [less than (&lt;) 140/90], and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting or diarrhea must persist at grade 3 or 4 despite maximal medical therapy.</description>
        <time_frame>Cycle 1 (28 days)</time_frame>
        <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
            <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
            <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O5">
            <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O7">
            <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O8">
            <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
            <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O9">
            <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
            <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O10">
            <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
            <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O11">
            <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
            <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)</title>
          <description>Dose-limiting toxicity (DLT) was defined as any of the following: Hematologic- prolonged grade 4 neutropenia for &gt;7 days. Febrile neutropenia, defined as grade 4 neutropenia with fever greater than (&gt;)38.5 degree Celsius, both sustained over a 24 hour period, neutropenic infection: greater than or equal to (&gt;=)Grade 3 neutropenia with Grade &gt;=3 infection. Grade &gt;=3 thrombocytopenia with bleeding or grade 4 lasting &gt;=7 days Lymphopenia was not considered a DLT unless accompanied by infection. Other non-hematologic toxicity: Grade 3 or 4 toxicities (except for alopecia, Grade 3/4 hypophosphatemia, grade 3 hypertension with controlled blood pressure [less than (&lt;) 140/90], and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting or diarrhea must persist at grade 3 or 4 despite maximal medical therapy.</description>
          <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of MidaZolam When Taken Alone or Taken With Crizotinib</title>
        <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
        <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Day -7 (midazolam alone arm), pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Cycle 2 Day 1 (midaZolam with crizotinib arm)</time_frame>
        <population>The PK concentration population of midazolam included all participants treated with midazolam (including Day -7 dose) who have at least 1 concentration of midazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD (Midazolam Alone)</title>
            <description>Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD + Midazolam</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID (Midazolam Alone)</title>
            <description>Participants who did not receive Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet BID on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID + Midazolam</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID along with 2 mg oral dose of Midazolam on Cycle 2 Day 1.</description>
          </group>
          <group group_id="O5">
            <title>RP2D Cohort: Crizotinib 250 mg (Midazolam Alone)</title>
            <description>Participants who did not receive Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O6">
            <title>RP2D Cohort: Crizotinib 250 mg + Midazolam</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) BID along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of MidaZolam When Taken Alone or Taken With Crizotinib</title>
          <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
          <population>The PK concentration population of midazolam included all participants treated with midazolam (including Day -7 dose) who have at least 1 concentration of midazolam.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.98" spread="19"/>
                    <measurement group_id="O2" value="19.26" spread="38"/>
                    <measurement group_id="O3" value="13.65" spread="10"/>
                    <measurement group_id="O4" value="32.62" spread="40"/>
                    <measurement group_id="O5" value="12.78" spread="41"/>
                    <measurement group_id="O6" value="25.37" spread="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>131.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.59</ci_lower_limit>
            <ci_upper_limit>179.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>239.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>172.14</ci_lower_limit>
            <ci_upper_limit>331.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>201.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>139.33</ci_lower_limit>
            <ci_upper_limit>291.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of MidaZolam When Taken Alone or Taken With Crizotinib</title>
        <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
        <time_frame>pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Day -7 (midazolam alone arm), pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Cycle 2 Day 1 (midaZolam with crizotinib arm)</time_frame>
        <population>The PK concentration population of midazolam included all participants treated with midazolam (including Day -7 dose) who have at least 1 concentration of midazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD (Midazolam Alone)</title>
            <description>Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD + Midazolam</title>
            <description>Participants received Crizotinib 100 mg capsule or tablet orally QD along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID (Midazolam Alone)</title>
            <description>Participants who did not receive Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet BID on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
          </group>
          <group group_id="O4">
            <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID + Midazolam</title>
            <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID along with 2 mg oral dose of Midazolam on Cycle 2 Day 1.</description>
          </group>
          <group group_id="O5">
            <title>RP2D Cohort: Crizotinib 250 mg (Midazolam Alone)</title>
            <description>Participants who did not receive Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet on Day -7, received single 2 mg oral dose of Midazolam on Day -7</description>
          </group>
          <group group_id="O6">
            <title>RP2D Cohort: Crizotinib 250 mg +Midazolam</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) BID along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of MidaZolam When Taken Alone or Taken With Crizotinib</title>
          <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).</description>
          <population>The PK concentration population of midazolam included all participants treated with midazolam (including Day -7 dose) who have at least 1 concentration of midazolam.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.77" spread="27"/>
                    <measurement group_id="O2" value="90.78" spread="33"/>
                    <measurement group_id="O3" value="37.71" spread="38"/>
                    <measurement group_id="O4" value="151.45" spread="31"/>
                    <measurement group_id="O5" value="32.10" spread="36"/>
                    <measurement group_id="O6" value="112.78" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>216.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>161.41</ci_lower_limit>
            <ci_upper_limit>289.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>350.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>141.09</ci_lower_limit>
            <ci_upper_limit>868.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>365.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>263.22</ci_lower_limit>
            <ci_upper_limit>507.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>RP2D Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Crizotinib When Taken With Food</title>
        <description>AUC0-24 of Crizotinib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.</description>
        <time_frame>pre-dose, 1, 2, 4, 6, 8, 9, and 24 hours post-dose on Day -7</time_frame>
        <population>The food effect analysis set included all participants treated (including Day -7 dose) and in the RP2D cohort who had received a dose of crizotinib under fed conditions and for which at least 1 PK parameter of interest (Cmax or AUC) was available. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg With Food</title>
            <description>Participants who were enrolled in enriched RP2D cohort received single dose of Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally with food on Day -7.</description>
          </group>
        </group_list>
        <measure>
          <title>RP2D Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Crizotinib When Taken With Food</title>
          <description>AUC0-24 of Crizotinib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.</description>
          <population>The food effect analysis set included all participants treated (including Day -7 dose) and in the RP2D cohort who had received a dose of crizotinib under fed conditions and for which at least 1 PK parameter of interest (Cmax or AUC) was available. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1212.86" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>RP2D Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken With Food</title>
        <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
        <time_frame>pre-dose, 1, 2, 4, 6, 8, 9, and 24 hours post-dose on Day -7</time_frame>
        <population>The food effect analysis set included all participants treated (including Day -7 dose) and in the RP2D cohort who had received a dose of crizotinib under fed conditions and for which at least 1 PK parameter of interest (Cmax or AUC) was available. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg With Food</title>
            <description>Participants who were enrolled in enriched RP2D cohort received single dose of Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally with food on Day -7.</description>
          </group>
        </group_list>
        <measure>
          <title>RP2D Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken With Food</title>
          <description>Cmax is defined as the observed maximum plasma concentration post drug administration.</description>
          <population>The food effect analysis set included all participants treated (including Day -7 dose) and in the RP2D cohort who had received a dose of crizotinib under fed conditions and for which at least 1 PK parameter of interest (Cmax or AUC) was available. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.24" spread="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin</title>
        <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau).</description>
        <time_frame>pre-dose, 2, 4, 6, 8 and 10 hours on Cycle 1 Day 15 (Crizotinib alone arm) and Cycle 2 Day 1 (Crizotinib with Rifampin arm)</time_frame>
        <population>PK parameter population was defined as all participants in the Rifampin interaction cohort safety population who satisfied following criteria for Cycle 1 Day 15 or Cycle 2 Day 1: a) had at least 1 of the primary PK parameters of Crizotinib (AUCtau and Cmax). b) received adequate dosing prior to PK sampling. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg Alone</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg With Rifampin</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) form Cycle 1Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin</title>
          <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau).</description>
          <population>PK parameter population was defined as all participants in the Rifampin interaction cohort safety population who satisfied following criteria for Cycle 1 Day 15 or Cycle 2 Day 1: a) had at least 1 of the primary PK parameters of Crizotinib (AUCtau and Cmax). b) received adequate dosing prior to PK sampling. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3110" spread="49"/>
                    <measurement group_id="O2" value="509.6" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric mean</param_type>
            <param_value>15.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.89</ci_lower_limit>
            <ci_upper_limit>22.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin</title>
        <time_frame>pre-dose, 2, 4, 6, 8 and 10 hours on Cycle 1 Day 15 (Crizotinib alone) and Cycle 2 Day 1 (Crizotinib with Rifampin)</time_frame>
        <population>PK parameter population was defined as all participants in the Rifampin interaction cohort safety population who satisfied following criteria for Cycle 1 Day 15 or Cycle 2 Day 1: a) had at least 1 of the primary PK parameters of Crizotinib (AUCtau and Cmax). b) Received adequate dosing prior to PK sampling. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg Alone</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg With Rifampin</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) form Cycle 1Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin</title>
          <population>PK parameter population was defined as all participants in the Rifampin interaction cohort safety population who satisfied following criteria for Cycle 1 Day 15 or Cycle 2 Day 1: a) had at least 1 of the primary PK parameters of Crizotinib (AUCtau and Cmax). b) Received adequate dosing prior to PK sampling. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326.4" spread="48"/>
                    <measurement group_id="O2" value="71.53" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric mean</param_type>
            <param_value>20.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.59</ci_lower_limit>
            <ci_upper_limit>29.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin</title>
        <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
        <time_frame>pre-dose on Cycle 1 Day 15 (Crizotinib alone arm) and Cycle 2 Day 1 (Crizotinib with Rifampin arm)</time_frame>
        <population>PK parameter population was defined as all participants in the Rifampin interaction cohort safety population who satisfied following criteria for Cycle 1 Day 15 or Cycle 2 Day 1: a) had at least 1 of the primary PK parameters of Crizotinib (AUCtau and Cmax). b) Received adequate dosing prior to PK sampling. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg Alone</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg With Rifampin</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) form Cycle 1Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin</title>
          <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
          <population>PK parameter population was defined as all participants in the Rifampin interaction cohort safety population who satisfied following criteria for Cycle 1 Day 15 or Cycle 2 Day 1: a) had at least 1 of the primary PK parameters of Crizotinib (AUCtau and Cmax). b) Received adequate dosing prior to PK sampling. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.7" spread="46"/>
                    <measurement group_id="O2" value="26.67" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole</title>
        <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 24 hours.</description>
        <time_frame>pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15 (Crizotinib with itraconazole) and Cycle 2 Day 1 (itraconazole alone)</time_frame>
        <population>PK parameter evaluable population included participants who had at least 1 of the PK parameters of Crizotinib (AUCtau or Cmax) and had received 10 consecutive doses of both Crizotinib 250 mg QD and itraconazole 200 mg QD immediately prior to end of Crizotinib 250 mg + Itraconazole treatment as well as 10 consecutive doses of Crizotinib 250 mg QD prior to end of Crizotinib 250 mg + Itraconazole treatment. Overall number of participants analyzed =participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone</title>
            <description>Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>Itraconazole Interaction Cohort: Crizotinib 250 mg + Itraconazole</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16. (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole</title>
          <description>Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval is 24 hours.</description>
          <population>PK parameter evaluable population included participants who had at least 1 of the PK parameters of Crizotinib (AUCtau or Cmax) and had received 10 consecutive doses of both Crizotinib 250 mg QD and itraconazole 200 mg QD immediately prior to end of Crizotinib 250 mg + Itraconazole treatment as well as 10 consecutive doses of Crizotinib 250 mg QD prior to end of Crizotinib 250 mg + Itraconazole treatment. Overall number of participants analyzed =participants evaluable for this outcome measure.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4102" spread="31"/>
                    <measurement group_id="O2" value="6665" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>157.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>136.89</ci_lower_limit>
            <ci_upper_limit>180.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole</title>
        <time_frame>pre-dose, 1, 2, 4, 6, 8, 9 and 24 hours post dose on Cycle 1 Day 15 (Crizotinib with itraconazole) and Cycle 2 Day 1 (itraconazole alone)</time_frame>
        <population>PK parameter evaluable population included participants who had at least 1 of the PK parameters of Crizotinib (AUCtau or Cmax) and had received 10 consecutive doses of both Crizotinib 250 mg QD and itraconazole 200 mg QD immediately prior to end of Crizotinib 250 mg + Itraconazole treatment as well as 10 consecutive doses of Crizotinib 250 mg QD prior to end of Crizotinib 250 mg + Itraconazole treatment. Overall number of participants analyzed =participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone</title>
            <description>Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg With Itraconazole</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16. (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole</title>
          <population>PK parameter evaluable population included participants who had at least 1 of the PK parameters of Crizotinib (AUCtau or Cmax) and had received 10 consecutive doses of both Crizotinib 250 mg QD and itraconazole 200 mg QD immediately prior to end of Crizotinib 250 mg + Itraconazole treatment as well as 10 consecutive doses of Crizotinib 250 mg QD prior to end of Crizotinib 250 mg + Itraconazole treatment. Overall number of participants analyzed =participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.9" spread="23"/>
                    <measurement group_id="O2" value="353.2" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio of adjusted geometric means</param_type>
            <param_value>132.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>119.10</ci_lower_limit>
            <ci_upper_limit>148.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole</title>
        <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
        <time_frame>pre-dose on Cycle 1 Day 15 (crizotinib with itraconazole) and Cycle 2 Day 1 (itraconazole alone)</time_frame>
        <population>PK parameter evaluable population included participants who had at least 1 of the PK parameters of Crizotinib (AUCtau or Cmax) and had received 10 consecutive doses of both Crizotinib 250 mg QD and itraconazole 200 mg QD immediately prior to end of Crizotinib 250 mg + Itraconazole treatment as well as 10 consecutive doses of Crizotinib 250 mg QD prior to end of Crizotinib 250 mg + Itraconazole treatment. Overall number of participants analyzed =participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone</title>
            <description>Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg With Itraconazole</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16. (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole</title>
          <description>Ctrough refers to plasma concentration of Crizotinib observed just before treatment administration.</description>
          <population>PK parameter evaluable population included participants who had at least 1 of the PK parameters of Crizotinib (AUCtau or Cmax) and had received 10 consecutive doses of both Crizotinib 250 mg QD and itraconazole 200 mg QD immediately prior to end of Crizotinib 250 mg + Itraconazole treatment as well as 10 consecutive doses of Crizotinib 250 mg QD prior to end of Crizotinib 250 mg + Itraconazole treatment. Overall number of participants analyzed =participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.0" spread="36"/>
                    <measurement group_id="O2" value="214.0" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)</title>
        <description>ORR was defined as participants with a best overall response of complete response (CR) or partial response (PR) divided by the total number of evaluable participants per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response.</description>
        <time_frame>Baseline up to 172 months</time_frame>
        <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants Analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).</description>
          </group>
          <group group_id="O5">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O6">
            <title>RP2D Cohort: Enriched Other: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)</title>
          <description>ORR was defined as participants with a best overall response of complete response (CR) or partial response (PR) divided by the total number of evaluable participants per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response.</description>
          <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants Analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="116"/>
                <count group_id="O6" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="57.7" upper_limit="83.2"/>
                    <measurement group_id="O2" value="32.3" lower_limit="21.2" upper_limit="45.1"/>
                    <measurement group_id="O3" value="31.6" lower_limit="17.5" upper_limit="48.7"/>
                    <measurement group_id="O4" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O5" value="61.2" lower_limit="51.7" upper_limit="70.1"/>
                    <measurement group_id="O6" value="8.3" lower_limit="0.2" upper_limit="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)</title>
        <description>Duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of progressive disease (PD) or death due to any cause. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
        <time_frame>From first documentation of response to date of PD or death due to any cause (up to 172 months)</time_frame>
        <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants who were objective responders. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)</title>
          <description>Duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of progressive disease (PD) or death due to any cause. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
          <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants who were objective responders. Data was planned to be analyzed for reported arms only.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="2.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="6.8" lower_limit="2.8" upper_limit="13.4"/>
                    <measurement group_id="O3" value="5.2" lower_limit="3.8" upper_limit="12.2"/>
                    <measurement group_id="O4" value="26.2" lower_limit="8.1" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)</title>
        <description>TTR: time between first dose until first documented response of PR or CR. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response.</description>
        <time_frame>From first dose until first documented response of PR or CR (up to 172 months)</time_frame>
        <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants who were objective responders. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)</title>
          <description>TTR: time between first dose until first documented response of PR or CR. PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response.</description>
          <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants who were objective responders. Data was planned to be analyzed for reported arms only.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="4.3" upper_limit="103.6"/>
                    <measurement group_id="O2" value="7.6" lower_limit="3.7" upper_limit="47.3"/>
                    <measurement group_id="O3" value="8.0" lower_limit="7.1" upper_limit="23.6"/>
                    <measurement group_id="O4" value="7.7" lower_limit="4.3" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8</title>
        <description>Disease control was defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.</description>
        <time_frame>Week 8</time_frame>
        <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8</title>
          <description>Disease control was defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.</description>
          <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" lower_limit="74.7" upper_limit="94.5"/>
                    <measurement group_id="O2" value="71.8" lower_limit="61.0" upper_limit="81.0"/>
                    <measurement group_id="O3" value="79.3" lower_limit="70.8" upper_limit="86.3"/>
                    <measurement group_id="O4" value="47.6" lower_limit="25.7" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16</title>
        <description>Disease control was defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.</description>
        <time_frame>Week 16</time_frame>
        <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16</title>
          <description>Disease control was defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) per RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PR: At least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum), without progression of non-target lesions and no appearance of new lesions indicated partial response. CR: Disappearance of all target and non-target lesions, normalization of tumor marker levels, and no appearance of new lesions indicated complete response. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.</description>
          <population>Response-evaluable population was defined as all participants in the SA set who had an adequate baseline disease assessment and had met 1 of the following 2 criteria: a) Had at least one post-baseline disease assessment b) withdrew from the trial or experienced progression/death at any time on study. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="65.9" upper_limit="89.2"/>
                    <measurement group_id="O2" value="51.8" lower_limit="40.7" upper_limit="62.7"/>
                    <measurement group_id="O3" value="67.2" lower_limit="57.9" upper_limit="75.7"/>
                    <measurement group_id="O4" value="42.9" lower_limit="21.8" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)</title>
        <description>Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
        <time_frame>From randomization until PD or death, whichever occurred first (up to 172 months)</time_frame>
        <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)</title>
          <description>Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
          <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="15.2" upper_limit="39.1"/>
                    <measurement group_id="O2" value="7.6" lower_limit="5.6" upper_limit="9.1"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.9" upper_limit="6.9"/>
                    <measurement group_id="O4" value="10.0" lower_limit="8.2" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6</title>
        <description>Probability of being event free (event defined as PD or death due to any cause) at 6 months after the first dose of crizotinib was reported. PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
        <time_frame>From randomization to 6 months</time_frame>
        <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall Number of Participants Analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6</title>
          <description>Probability of being event free (event defined as PD or death due to any cause) at 6 months after the first dose of crizotinib was reported. PD: &gt;=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.</description>
          <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall Number of Participants Analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
          <units>Probability of being event-free</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="62.8" upper_limit="86.1"/>
                    <measurement group_id="O2" value="57.5" lower_limit="45.3" upper_limit="68.0"/>
                    <measurement group_id="O3" value="39.0" lower_limit="22.8" upper_limit="54.9"/>
                    <measurement group_id="O4" value="71.9" lower_limit="61.8" upper_limit="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)</title>
        <description>OS was defined as the time from randomization to death due to any cause.</description>
        <time_frame>From randomization date to the date of death (up to 172 Months)</time_frame>
        <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)</title>
          <description>OS was defined as the time from randomization to death due to any cause.</description>
          <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" lower_limit="29.3" upper_limit="NA">Upper limit of 95% CI could not be estimable due to low number of participants with events.</measurement>
                    <measurement group_id="O2" value="20.0" lower_limit="13.2" upper_limit="25.7"/>
                    <measurement group_id="O3" value="10.1" lower_limit="7.1" upper_limit="12.9"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI could not be estimable due to low number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Probability of Participant Survival at Month 6</title>
        <description>Probability of survival was defined as the probability of being alive at Month 6.</description>
        <time_frame>Month 6</time_frame>
        <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of Participant Survival at Month 6</title>
          <description>Probability of survival was defined as the probability of being alive at Month 6.</description>
          <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall number of participants analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
          <units>Probability of participants survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="78.7" upper_limit="95.9"/>
                    <measurement group_id="O2" value="86.7" lower_limit="77.3" upper_limit="92.4"/>
                    <measurement group_id="O3" value="67.8" lower_limit="51.1" upper_limit="79.9"/>
                    <measurement group_id="O4" value="90.0" lower_limit="82.7" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Probability of Participant Survival at Month 12</title>
        <description>Probability of survival was defined as the probability of being alive at Month 12.</description>
        <time_frame>Month 12</time_frame>
        <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall Number of Participants Analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O2">
            <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O3">
            <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
          </group>
          <group group_id="O4">
            <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of Participant Survival at Month 12</title>
          <description>Probability of survival was defined as the probability of being alive at Month 12.</description>
          <population>SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, &quot;Overall Number of Participants Analyzed&quot; signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.</population>
          <units>probability of participants survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" lower_limit="65.0" upper_limit="87.7"/>
                    <measurement group_id="O2" value="66.0" lower_limit="54.0" upper_limit="75.5"/>
                    <measurement group_id="O3" value="37.1" lower_limit="22.4" upper_limit="51.8"/>
                    <measurement group_id="O4" value="80.5" lower_limit="70.9" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 1 Day 15</title>
        <description>Geometric mean of ratio (Cycle1Day15/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
        <time_frame>Baseline, Cycle 1 Day 15</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 1 Day 15</title>
          <description>Geometric mean of ratio (Cycle1Day15/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.34" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.42" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.91" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Luteinizing Hormone (LH) Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.47" upper_limit="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.66" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.66" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="0.32" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.85" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 2 Day 1</title>
        <description>Geometric mean of ratio (Cycle 2 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
        <time_frame>Baseline, Cycle 2 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 2 Day 1</title>
          <description>Geometric mean of ratio (Cycle 2 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" lower_limit="0.38" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.56" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.71" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.26" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.48" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="0.97" upper_limit="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.18" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.75" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 4 Day 1</title>
        <description>Geometric mean of ratio (Cycle 4 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
        <time_frame>Baseline, Cycle 4 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 4 Day 1</title>
          <description>Geometric mean of ratio (Cycle 4 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.27" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.49" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="0.55" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.57" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.68" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" lower_limit="0.88" upper_limit="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.18" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.69" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 6 Day 1</title>
        <description>Geometric mean of ratio (Cycle 6 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
        <time_frame>Baseline, Cycle 6 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 6 Day 1</title>
          <description>Geometric mean of ratio (Cycle 6 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.24" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.58" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.48" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="0.60" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.78" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.01" upper_limit="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.15" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.68" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 9 Day 1</title>
        <description>Geometric mean of ratio (Cycle 9 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, Cycle 9 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 9 Day 1</title>
          <description>Geometric mean of ratio (Cycle 9 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.26" upper_limit="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" lower_limit="0.49" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.65" upper_limit="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.56" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.67" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="1.08" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.09" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.51" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 12 Day 1</title>
        <description>Geometric mean of ratio (Cycle 12 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, Cycle 12 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 12 Day 1</title>
          <description>Geometric mean of ratio (Cycle 12 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.14" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.32" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.72" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.59" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.63" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" lower_limit="0.68" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.11" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.42" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 15 Day 1</title>
        <description>Geometric mean of ratio (Cycle 15 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, Cycle 15 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 15 Day 1</title>
          <description>Geometric mean of ratio (Cycle 15 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this outcome measure.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.21" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.47" upper_limit="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="0.86" upper_limit="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.56" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.53" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="0.57" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.12" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.57" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 18 Day 1</title>
        <description>Geometric mean of ratio (Cycle 18 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, Cycle 18 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 18 Day 1</title>
          <description>Geometric mean of ratio (Cycle 18 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.22" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" lower_limit="0.03" upper_limit="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="1.12" upper_limit="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.58" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.53" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.42" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.07" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.20" upper_limit="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 21 Day 1</title>
        <description>Geometric mean of ratio (Cycle 21 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, Cycle 21 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 21 Day 1</title>
          <description>Geometric mean of ratio (Cycle 21 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.09" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="0.62" upper_limit="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.12" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.44" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.00" upper_limit="797.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.00" upper_limit="20.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.09" upper_limit="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 24 Day 1</title>
        <description>Geometric mean of ratio (Cycle 24 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, Cycle 24 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 24 Day 1</title>
          <description>Geometric mean of ratio (Cycle 24 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.00" upper_limit="70772.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" lower_limit="0.00" upper_limit="11581.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.10" upper_limit="12.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.09" upper_limit="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.07" upper_limit="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.00" upper_limit="33217.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.48" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 27 Day 1</title>
        <description>Geometric mean of ratio (Cycle 27 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, Cycle 27 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 27 Day 1</title>
          <description>Geometric mean of ratio (Cycle 27 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this outcome measure.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.00" upper_limit="61000.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.00" upper_limit="9022.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="0.11" upper_limit="20.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" lower_limit="0.11" upper_limit="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.06" upper_limit="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" lower_limit="0.02" upper_limit="147.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.00" upper_limit="22059.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.24" upper_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 30 Day 1</title>
        <description>Geometric mean of ratio (Cycle 30 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, Cycle 30 Day 1</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 30 Day 1</title>
          <description>Geometric mean of ratio (Cycle 30 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this outcome measure.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at End of Treatment</title>
        <description>Geometric mean of ratio (End of treatment/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
        <time_frame>Baseline, End of Treatment (28 days post last dose)</time_frame>
        <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>RP2D Cohort: Crizotinib 250 mg</title>
            <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at End of Treatment</title>
          <description>Geometric mean of ratio (End of treatment/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.</description>
          <population>Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. &quot;N&quot; =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.08" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.39" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="0.49" upper_limit="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH Serum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.14" upper_limit="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.26" upper_limit="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.20" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Hormone Binding Globulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="0.24" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydroepiandrosterone Sulfate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.21" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until 28 days after the last dose day of study drug (up to 172 months)</time_frame>
      <desc>Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Analysis performed on safety analysis set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Escalation Cohort: Crizotinib 50 mg QD</title>
          <description>Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Escalation Cohort: Crizotinib 100 mg QD</title>
          <description>Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
        </group>
        <group group_id="E3">
          <title>Low Dose Escalation Cohort: Crizotinib 200 mg QD</title>
          <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E4">
          <title>Low Dose Escalation Cohort: Crizotinib 200 mg BID</title>
          <description>Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E5">
          <title>Low Dose Escalation Cohort: Crizotinib 250 mg BID</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E6">
          <title>Low Dose Escalation Cohort: Crizotinib 300 mg BID</title>
          <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.</description>
        </group>
        <group group_id="E7">
          <title>High Dose Escalation Cohort: Crizotinib 300 mg QD</title>
          <description>Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E8">
          <title>High Dose Escalation Cohort: Crizotinib 400 mg QD</title>
          <description>Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E9">
          <title>High Dose Escalation Cohort: Crizotinib 500 mg QD</title>
          <description>Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E10">
          <title>High Dose Escalation Cohort: Crizotinib 650 mg QD</title>
          <description>Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E11">
          <title>High Dose Escalation Cohort: Crizotinib 800 mg QD</title>
          <description>Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E12">
          <title>RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E13">
          <title>RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E14">
          <title>RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E15">
          <title>RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days).</description>
        </group>
        <group group_id="E16">
          <title>RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).</description>
        </group>
        <group group_id="E17">
          <title>RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E18">
          <title>RP2D Cohort: Enriched Other: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).</description>
        </group>
        <group group_id="E19">
          <title>Itraconazole Interaction Sub-study: Crizotinib 250 mg</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.</description>
        </group>
        <group group_id="E20">
          <title>RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin</title>
          <description>Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.</description>
        </group>
        <group group_id="E21">
          <title>Midazolam Interaction Cohort: Crizotinib 250</title>
          <description>Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID from Day 1Cycle 1 up to p to 133 cycles (each cycle 28 days). Participants also received single 2 mg oral dose of Midazolam on Day -7 and another single 2-mg oral dose of Midazolam concurrently with Crizotinib on Cycle 2 Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="25" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="24" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="54" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="25" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="22" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="75" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="29" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="19" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Physical deconditioning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fat necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mesenteric abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Septic arthritis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Foetal exposure during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Adult failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fracture pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Soft tissue disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Central nervous system haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="53" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="85" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="46" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="154" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="66" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="17" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="14" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="26" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Excessive cerumen production</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="43" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="26" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="92" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="22" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Retinal drusen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Swelling of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Visual brightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vitreous degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="19" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="24" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="45" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="21" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="68" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="25" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="50" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="17" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="17" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="93" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="32" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="19" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="17" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="33" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="49" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="20" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="97" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="41" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="12" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="28" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="35" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="26" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="81" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="34" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Duodenogastric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gingival discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral blood blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Salivary gland disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="14" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="16" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="20" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="35" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="23" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="59" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="26" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="14" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="27" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="49" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="69" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="18" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="34" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Breakthrough pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="17" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple allergies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="26" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="39" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="19" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Optic nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stoma site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="17" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="35" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="30" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="28" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="33" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Iron binding capacity total decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mean cell haemoglobin concentration decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nitrite urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Red cell distribution width increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Serum ferritin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Transferrin saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vital dye staining cornea present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Waist circumference increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="24" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="50" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="29" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="22" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="32" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="20" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="27" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="18" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Limb mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oncologic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="21" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="25" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="12" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="65" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="34" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="21" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="18" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Visual perseveration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="26" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="24" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="24" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="27" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="11" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="34" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="19" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="17" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="41" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

